NCT03233854View on ClinicalTrials.gov

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2035

Conditions
B Acute Lymphoblastic LeukemiaCD19 PositiveMinimal Residual DiseasePhiladelphia Chromosome Positive
Interventions
BIOLOGICAL

Chimeric Antigen Receptor T-Cell Therapy

Given CD19/CD22 CAR T cells IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

NKTR-255

Given IV

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Crystal Mackall, MD

OTHER